- Home
- RRC vs LEGN Comparison
RRC vs LEGN Comparison
Compare RRC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRC
- LEGN
- Stock Information
- Founded
- RRC 1976
- LEGN 2014
- Country
- RRC United States
- LEGN United States
- Employees
- RRC N/A
- LEGN N/A
- Industry
- RRC Oil & Gas Production
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- RRC Energy
- LEGN Health Care
- Exchange
- RRC Nasdaq
- LEGN Nasdaq
- Market Cap
- RRC 8.4B
- LEGN 6.7B
- IPO Year
- RRC N/A
- LEGN 2020
- Fundamental
- Price
- RRC $35.53
- LEGN $34.47
- Analyst Decision
- RRC Hold
- LEGN Strong Buy
- Analyst Count
- RRC 18
- LEGN 12
- Target Price
- RRC $43.06
- LEGN $73.36
- AVG Volume (30 Days)
- RRC 2.8M
- LEGN 1.1M
- Earning Date
- RRC 10-21-2025
- LEGN 11-11-2025
- Dividend Yield
- RRC 1.01%
- LEGN N/A
- EPS Growth
- RRC 0.32
- LEGN N/A
- EPS
- RRC 1.98
- LEGN N/A
- Revenue
- RRC $2,799,229,500.00
- LEGN $796,838,000.00
- Revenue This Year
- RRC $30.36
- LEGN $70.75
- Revenue Next Year
- RRC $14.88
- LEGN $52.47
- P/E Ratio
- RRC $17.96
- LEGN N/A
- Revenue Growth
- RRC 19.93
- LEGN 74.75
- 52 Week Low
- RRC $28.99
- LEGN $27.34
- 52 Week High
- RRC $43.50
- LEGN $52.15
- Technical
- Relative Strength Index (RSI)
- RRC 56.31
- LEGN 44.92
- Support Level
- RRC $34.69
- LEGN $32.70
- Resistance Level
- RRC $35.76
- LEGN $34.71
- Average True Range (ATR)
- RRC 0.89
- LEGN 1.21
- MACD
- RRC 0.26
- LEGN 0.07
- Stochastic Oscillator
- RRC 71.28
- LEGN 46.90
About RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.